1-[(S)-3-hydroxy-2-(phosphonomethoxy) propyl] cytosine, HPMPC] is an acyclic cytosine nucleotide analogue with potent in-vitro and in-vivo activity against a broad spectrum of herpesviruses including human cytomegalovirus (HCMV). Cidofovir has recently been shown to delay the progression of HCMV retinitis in AIDS patients. Therefore, the effects of several antiviral compounds (GCV, AZT, ddC, ddl, d4T, 3TC and PMEA) on the anti-HCMV activity of cldofovir were investigated in vitro. Cidofovir in combination with GCV demonstrated synergistic inhibition of HCMV replication. Very little significant antiviral synergy or antagonism was measured for any of the other combinations. Furthermore, none of the combinations showed increased cytotoxicity in comparison with each drug alone. Additionally, the antiviral activity of cidofovir was determined in the presence of several immunosuppressive agents (hydrocortisone, cyclosporine A, methotrexate and mycophenolic acid) that are commonly used in the management of organ transplantation rejection in transplant patients. None of these agents altered the antiviral activity of cidofovir in vitro.
Introduction
Human cytomegalovirus (HCMV) is one of the most common opportunistic infections in immunocompromised patients such as AIDS patients and organ transplant recipients. In AIDS patients, HCMV primarily causes retinitis and colitis (Macher et al., 1983; Tyms et et., 1989) , while in kidney, heart, liver and bone marrow transplant patients, it can cause serious interstitial pneumonitis (Meyers et al., 1986) .
Presently, ganciclovir (GCV) and foscarnet (PFA) are the only approved therapies for HCMV. Both of these compounds, however, have their limitations, including the development of drug resistance (Erice et al., 1989; Drew et al., 1991; Knox et al., 1991; Smith, I.L., et al., 1995, Abstracts of the 35th Interscience Conference on Antimicrobial Agents and Chemotherapy San Francisco, CA.: 200.) dose limiting toxicities (Masur et al., 1986; Ringden et al., 1986; Laskin et al., 1987; ) and confinement in a hospital. Cidofovir is a cytosine nucleotide analogue that possesses potent in-vitro and in-vivo activity against HCMV, and recently has been shown to significantly delay the time to HCMV retinitis progression (Kupperman et al., 1995) .
Cidofovir has a long intracellular half-life (Ho et al., 1992; Aduma et et., 1995) and, to date, resistance to cidofovir in the clinic as a result of cidofovir treatment has not been described (Cherrington et al., 1996) . Furthermore, cidofovir is effective against the majority of GCV resistant clinical isolates (those resulting from a defect in the protein coded for by UL97) (Stanat et et., 1991) , as well as PFA resistant viruses generated in vitro (Snoeck et el., 1995) and in vivo (unpublished observations) as a result of PFA treatment alone.
Since HCMV disease primarily occurs in two populations of patients (AIDS and organ transplant) who often receive multiple drugs for the treatment of more than one disease, it is critical to investigate the possible synergistic/antagonistic interactions that may occur between drug combinations. GCV and PFA have been shown to function synergistically to inhibit HCMV replication in vitro (Manischewitz et al., 1990) and to inhibit HCMV and herpes simplex virus type 2 (HSV-2) in vitro and in vivo (Freitas et al., 1989) . Snoeck et al. (1992) have demonstrated that cidofovir in combination with GCV, AZT, PFA or acyclovir showed additive to synergistic inhibitionof HCMV replication in vitro. While drug combination experiments involving antivirals and immunosuppressants have not been described in detail, several groups have shown the effects of various immunosuppressants alone on HCMV replication. Hydrocortisone increases HCMV replication in vitro (Tanaka et al., 1984; Forbes et al., 1990; Lathey and Spector, 1991); and in vivo (MacGregor et al., 1986) ; cyclosporine A also increases replication in vitro (Numazaki et al., 1994) ; and methotrexate inhibits HCMV replication in vitro (Shanley and Debs, 1989) .
In order to determine whether pertinent drug interactions might affect the antiviral activity of cidofovir in vitro, experiments involving combinations of cidofovir and other antiviral compounds, as well as immunosuppressive agents, were performed. The antiviral activity of cidofovir was not significantly compromised with any drug combination, nor did any combination result in increased cytotoxicity.
Results

Antiviral activity and cytotoxicity of compounds used in combination experiments
The antiviral and cytotoxic activities of cidofovir, GCV, AZT, ddC, ddl, d4T, 3TC and PMEA are shown in Table 1 . Cidofovir and GCV demonstrate potent anti-HCMV activity, with IC 5 0 values of 0.5 and 5.0 !!M, respectively. PMEA shows moderate anti-HCMV activity with an IC 5 0 value of 39 !!M. The remaining antiretroviral compounds do not exhibit any anti-HCMV activity up to 100 !!M. Very little cytotoxicity was measured for any of these compounds in normal human dermal fibroblast (NHDF) cells; all CC 5 0 values were> 100 !!M.
Determination of synergistic antiviral activity of cidofovir andGCV
Cidofovir and GCV had been shown previously to exert synergistic inhibition of HCMV replication (Snoeck et al., 1992) using the isobologram method (Saba et al., 1984) . Therefore, this same combination was evaluated for synergistic or antagonistic anti-HCMV activity using the MacSynergy II method (Prichard et al., 1993) . In agreement with the findings of Snoeck et al. (1992) , minor synergy was determined to exist for this combination using the MacSynergy II program (Prichard et al., 1993) , showing a synergy volume of approximately 25 !!M 2 % (Table 2 ). This "Assays were conducted as described in Materials and Experimental Procedures and represent mean values of two separate experiments. bCC so is defined as the concentration of drug that inhibits cell viability by 50%. clC so is defined as the concentration of drug that inhibits plaque number by 50%. synergy occurred at cidofovir concentrations between 0.03 !!M-3.0 !!M and GCV concentrations between 3.0 !!M-30 !!M. No antiviral antagonism was measured for the combination.
Determination of synergistic and antagonistic antiviral activity of ckiotovir in combination with antiretroviral compounds
In clinical trials, cidofovir in combination with five commonly used antiretroviral compounds (AZT, ddC, ddl, d4T, and 3TC) and one additional compound (PMEA) was assayed for anti-HCMV activity. The data were analysed using the MacSynergy II program (Prichard et al., 1993) and the results are shown in Table 2 . In agreement with Snoeck et al. (1992) , the combination of AZT and cidofovir demonstrated a small but probably insignificant degree of antiviral synergy, with a synergy volume of 9 !!M 2 % (Table 2) . This minor interaction occurred at AZT concentrations of 30 !!M-1 00 !!M and at cidofovir concentrations of 0.3 !!M-1 !!M. The combinations of ddC, ddl, d4T, 3TC and PMEA with cidofovir showed no synergistic antiviral activity (Table 2) . Minor, but probably insignificant, antiviral antagonism was shown to exist between d4T, 3TC and PMEA in combination with cidofovir; these combinations had antagonism volumes of 8, 12 and 22 !!M 2 %, respectively. This "Assays were conducted as described in Materials and Experimental Procedures and values represent the means of at least two separate experiments. bCC SO is defined as the concentration of drug that inhibits cell Viabilityby 50%. clC so is defined as the concentration of drug that inhibits plaque number by 50%.
Concentration of Immunosuppressant CCSO(JlM)b immunosuppressant (JlM)
Determination of synergistic and antagonistic cytotoxic effects of cidofovir in combination with antiretroviral compounds
In order to further investigate the potential interactions between the molecules analysed above for antiviral synergy/antagonism, similar drug combinations were analysed in uninfected cells for their ability to act synergistically (increase cell number/viability) or antagonistically (decrease cell number/viability) in their cytotoxicities. The combination effects of AZT, ddC, ddl, d4T, 3TC and PMEA with cidofovir on the cytotoxicity of uninfected normal human dermal fibroblast (NHDF) cells were evaluated at the same drug concentrations used for the antiviral combination experiments (Table 3) . Cidofovir in combination with ddC exhibited a minor amount of synergy with a volume of 27.5 flM 2%. This synergistic increase in cell number was measured over a wide range of cidofovir concentrations, 0.3 flM-10 flM, and at high concentrations of ddC (100 flM). No significant additional synergistic interactions were observed in the uninfected cells. No antagonistic interactions leading to increased cytotoxicity were measured for the drug combinations. 
Effect of immunosuppressive compounds on the anti-HCMV activity of cidofovir
The immunosuppressants cyclosporine A, hydrocortisone, methotrexate and mycophenolic acid were evaluated for their effects on the anti-HCMV activity of cidofovir. Initially, the CC so values of these four compounds were determined in NHDF cells and ranged from 0.1 11M to 500 CSynergy reflects a drug combination that results in an increase in cell viability (increase in absorbance at 450 nm in XTT assay). dAntagonism reflects a drug combination that results in a decrease in cell viability (decrease in absorbance at 450 nm in XTT assay).
flM (Table 4 ). SUbsequently, the compounds were tested at 1/10 the CC so value and one additional concentration in the presence of varying concentrations of cidofovir. None of the immunosuppressants tested had any effect on the anti-HCMV activity of cidofovir (Table 4 ). Of note, is the fact that 50 or 100 flM hydrocortisone, despite increasing HCMV replication two-to three-fold ( Fig. 1a) , had no effect on the IC so of cidofovir (Fig. 1b ). Cyclosporine A also moderately increased HCMV replication (approximately 22% at the concentrations tested; data not shown) yet had no effect on the IC so value of cidofovir. Shanley and Debs (1989) previously reported that methotrexate inhibited HCMV replication with an IC so value of 0.06 flM. It was found that methotrexate alone inhibited HCMV replication approximately 20% at the concentrations tested (data not shown), but again had no effect on the IC so value of cidofovir. Mycophenolic acid had no effect on HCMV replication or on the IC so value of cidofovir at the concentrations tested.
Discussion
Cidofovir is a potent inhibitor of HCMV replication. HCMV retinitis occurs in 20-40% of AIDS patients and can lead to blindness; cidofovir has been reported to delay the progression of CMV retinitis in this patient population (Kuppermann et al., 1995 
Materials and Experimental Procedures
Nucleotides and chemicals 1-[ (8)-S-hyd roxy-2-(phosph onomethoxy) propyllcytosi ne (HPMPC, cidofovir) was synthesized according to the methods of Holy and Rosenberg (1989) . 9-[2-(phosphonomethoxy)sthyljadenlne (PMEA, adefovir) was synthesized according to the methods of Holy and Rosenberg (1987) . (9-[(2-hydroxyl-1hydroxymethyl)ethoxymethyllguanine (DHPG, ganciclovir) was purchased from Syntex (Roche) (Palo Alto, CA). 2',S'-didehydro-2',S'-dideoxylhymidine (D4T or stavudine) was a gift from Bristol Myers Squibb (Wallingford, CT). 2',S'-dideoxy-S'-thiacytidine (STC) was a gift from Glaxo Wellcome (Middlesex, UK). MEM Earl's Salts tissue culture medium, fetal bovine serum and antibiotics were obtained from Irvine Scientific (Santa Ana, CA). Cyclosporine A was purchased from Sandoz (East Hanover, NJ). S'-azido-S'-deoxylhymidine (AZT), 2',S'-dideoxycylidine (ddC), 2',S'-dideoxyinosine (ddl), 2,S-bis(2-methoxy-4-nitro-5sulphophenyl)-[(phenylamino)carbonyI1-2H-tetrazolium-hydroxide (XIT), crystal violet, phenazine methosulphate (PMS), methotrexate, mycophenolic acid and hydrocortisone were purchased from Sigma Chemical Co. (St. Louis, MO). nations did not display increased cytotoxicity. In agreement with published literature (Snoeck et al., 1992) , the data here also showed that cidofovir has antiviral synergy with GCV.
In addition to causing significant disease in AIDS patients, CMV disease is a considerable cause of morbidity and mortality in the organ transplant population. Potentially, cidofovir may be used as an antiviral therapy in this setting. Therefore, it was important to identify any effect of the commonly used immunosuppressive agents on the anti-HCMV activity of cidofovir. The data presented here show that even though some of these compounds are able to increase HCMV replication, the efficacy of cidofovir is unaltered.
Based on the results of the in-vitro drug combination experiments presented here, cidofovir drug combinations should be efficacious and well tolerated. Clearly, combinations of approved drugs are currently commonly used for the treatment of HCMV disease in AIDS patients and in transplant recipients. The future use of cidofovir in combination with antiviral agents or immunosuppressants may lead to the beneficial management of HCMV disease in these patient populations. (Geneva, Switzerland». Since these patients are likely to be receiving at least one antiretroviral agent, it was critical to determine whether such agents would influence the antiviral effect of cidofovir. The data presented here demonstrates that the anti-HCMV activity of cidofovir was not altered by any of the anti-HIV drugs or by one additional clinical candidate, PMEA, currently in clinical trials for the treatment of AIDS. Furthermore, these drug combi-
Cells and virus
NHDF (normal human dermal fibroblasts-foreskin) cells were purchased from Clonetics (San Diego, CA) and maintained in MEM Earl's Salts tissue culture medium supplemented with fetal bovine serum (10%), glutamine (2 mM), non-essential amino acids and antibiotics, and used prior to passage 15. The Towne strain of HCMV was purchased from ATCC (American Type Culture Collection, Rockville, MD).
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Determination of synergistic or antagonistic antiviral effects of drug combinations in vitro: ckiotovir and antivifalcompounds Antiviral activity against HCMV was determined using a modified plaque reduction assay in NHDF cells. For each drug combination, four 24 well plates were used to form a 96 well grid. Each combination was performed in triplicate, so 12 plates were used for each drug combination. These plates contained a newly confluent monolayer of NHDF cells and were infected with the Towne strain of HCMV at a multiplicity of infection (MOl) of 40-50 PFU/well. After 3 h the virus was removed and replaced with growth media. One compound was then diluted by thirds vertically, the other compound was diluted by thirds horizontally (there are eight different vertical concentrations and 11 different horizontal concentrations). One column of wells received no drug to serve as an untreated infected control. After 7 days, the cells were fixed and stained with 10% methanollO.1% crystal violet and plaques were counted under low field microscopy. The plaque number per well was counted for each combination of the two drugs, and entered into the MacSynergy II program (Prichard et el., 1993) for determination of synergistic/antagonistic effects of combinations.
Determination of synergistic or antagonistic entiviret effects of drug combinations in vitro: ckiotovir and immunosuppressive compounds
The anti-HCMV activity of cidofovir in the presence of immunosuppressants was determined using a plaque reduction assay in 24 well plates. NHDF cells were infected with the Towne strain of HCMV as described above. Cidofovir was then diluted by thirds vertically in media alone and in the presence of two fixed concentrations of one immunosuppressant. Each combination was performed in duplicate. After 7 days the cells were fixed and stained as described above. The plaque number per well was counted for each combination of the two drugs, and the data were plotted as percentage inhibition of the average plaque number vs. the concentration of drugs; the antiviral inhibition curves were fitted using Deltagraph Professional Software. The IC so value of cidofovir is defined as the concentration of drug that decreased the number of plaques to 50% of the number present in the control wells with no drug. The individual anti-HCMV activity of the four immunosuppressants was also determined using this plaque reduction assay.
Synergy/antagonism of drug combinations on uninfected cell growth
Cytotoxicity of the drug combinations was determined using a newly confluent monolayer of uninfected NHDF cells in a 96 well plate. One drug was diluted by thirds vertically and the other drug by thirds horizontally. All combinations were performed in triplicate. At the end of 7 days, an xn assay (Roehm et al., 1991) was performed. Data was analysed by the MacSynergy II program (Prichard et al., 1993) . The individual cytotoxic effects of the immunosuppressants and the other antiviral compounds were also determined using this xn
In-vitro activity of cidofovir drug combinations 207 assay. The CC so value of a molecule is defined as the concentration of drug that decreases the xn signal (absorbance at 450 nm) by 50% of that measured in an untreated well.
Analyses of drug combinations for synergistic/antagonistic interactions
The MacSynergy II program (Pritchard et al., 1993) was used to determine whether synergistic or antagonistic effects are evident from drug combination experiments. For antiviral assays, data is entered as plaque number per well at specific concentrations of two drugs and for cytotoxicity assays, data is entered as an absorbance value at 450 nm (from XTT assay) at specific concentrations of two drugs. The program then calculates the synergistic/antagonistic interactions occurring at each drug concentration present in the combination (defined by 3-dimensional dose response surfaces and subtracting out additive interactions) and finally represents the data as a volume of synergy or antagonism. These volumes are given in units of IlM2% and are analogous to the units for area under a dose response curve in 2-dimensions (IlM%). All of the interactions are calculated at 95%, 99% and 99.9% confidence intervals; the data presented here are from a 95% confidence interval.
